Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk

By Miyoshi Y.   Ando A.   Hasegawa S.   Ishitobi M.   Yamamura J.   Irahara N.   Tanji Y.   Taguchi T.   Tamaki Y.   Noguchi S.  

European Journal of Cancer, Vol. 39, Iss. 17, 2003-11 ,pp. : 2531-2537

Elsevier

Access to resources Recommend Favorite

Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients

By Carlini Paolo   Michelotti Andrea   Ferretti Gianluigi   Ricci Sergio   Giannarelli Diana   Pellegrini Manuela   Cresti Nicola   Cosimo Serena Di   Bria Emilio   Papaldo Paola   Fabi Alessandra   Ruggeri Enzo Maria   Milella Michele   Alimonti Andrea   Salesi Nello   Cognetti Francesco  

Cancer Investigation, Vol. 25, Iss. 2, 2007-03 ,pp. : 102-105

Informa Healthcare

Access to resources Recommend Favorite

Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 12, Iss. 2, 2017-06 ,pp. : 136-147

Bentham Science Publishers

Access to resources Recommend Favorite

Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)

By Artac Mehmet  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 174-180

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase Inhibitors for Treatment of Breast Cancer

By  

Current Cancer Therapy Reviews, Vol. 3, Iss. 1, 2007-02 ,pp. : 67-79

Bentham Science Publishers

Access to resources Recommend Favorite